Since the industrial revolution, there has been a collective Western consensus that technology would continue to propel our world forward, further strengthening our personal and professional lives.

Bristol Myers Squibb reported revenue of $11.1 billion in the fourth quarter, a 39% year-over-year jump. This easily topped the average analysts estimate of $10.7 billion. The company announced a net ...

Bristol Myers Squibb Co. (BMS) and Eisai Co. Ltd. inked a potential $3.1 billion agreement to co-develop and co-commercialize the antibody-drug conjugate (ADC) MORAb-202 for advanced solid tumors.

A drug that Bristol Myers Squibb is developing for use across a wide range of autoimmune diseases has failed a mid-stage clinical trial in ulcerative colitis, dimming its prospects in that indication.

Analog devices, Inc. ADI is making strong efforts to bolster presence in the automotive market on the back of robust Battery Management System (BMS) platform. The company’s latest introduction of ASIL ...

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file ...

Building on a deal first struck in 2019, artificial intelligence (AI) specialist Exscientia Ltd. has agreed to take responsibility for a multitarget drug discovery collaboration with Bristol Myers ...

The first cancer cell therapies were personalized treatments made by isolating and engineering a patient’s own T cells in the lab—a complex, cumbersome, and expensive process. A slew of companies are ...

Bristol Myers Squibb ponied up $13 billion for MyoKardia last fall, just months after it showed its targeted drug could prevent thickened heart muscle from blocking blood flow in patients with an ...

No one likes to miss the big party. But shareholders of Bristol Myers Squibb (NYSE: BMY) probably feel like they did in 2020. Shares of the drugmaker declined slightly last year while the overall ...